Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors – Yahoo Finance
YANGZHOU, China, Dec. 5, 2022 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced the appointments of Mr. Xin Wang as Chief Executive Officer and director, Mr. Lianzhang Zhao as Chief Financial Officer and Ms. Huijuan Zhao as independent board member, member of the compensation committee and audit committee, and chair of the nominating committee, effective as of December 1st, 2022, to fill the vacancies arising from the voluntary resignations of Mr. Yulin Wang as CEO, interim CFO and director of the Company due to the expiration of his employment contract, and Mr. Xu Han as independent board member, member of compensation committee and audit committee, and chair of nominating committee, who resigned for personal reasons.
Prior to joining MHUA, from 2021 until 2022, Mr. Xin Wang was CEO of the Jiangsu Yada Technology Group Co., Ltd., a PRC company that develops distributes medical devices. In addition, Mr. Wang served as Vice General Manager of Shanghai New Asia (Group) Co., Ltd., a pharmaceutical company, where he led production management, market expansion, research and development of proprietary Chinese traditional medicines from 2020 to 2021. From 2018 to 2020, Mr. Wang held a key position at Panda Group, Inc., a franchise restaurant corporation based in California, where he was in charge of large commercial projects related to expanding its business operations and upgrading its brand strategy in the US market. In addition, Mr. Wang worked as a financial analyst at Morgan Stanley and as area manager at Citibank, N.A., thus providing him insight into global investment banking and US financial markets. Mr. Wang obtained his bachelor’s degree from the University of California Santa Barbara, where he double majored in Financial Mathematics & Statistics Analysis and Computer Science. He also obtained his master’s degree in Actuarial Science in 2012 from UC Santa Barbara.
Prior to his appointment at MHUA, Mr. Lianzhang Zhao was Senior Partner at Yangzhou Hanrui Accounting Firm from 2013 to 2022. Prior to that, from 2000 to 2013, Mr. Zhao served as the chief financial officer of Yangzhou Guolian Garment Factory Co., which is a Sino-US joint venture company in China. Mr. Zhao is a certified public accountant (CPA) in China, allowing him to draw on his diverse financial accounting experience across multiple international markets to support MHUA’s financial reporting matters. Mr. Zhao holds bachelor’s degree in Financial Accounting and Economic Management in 1990 from Yangzhou University.
Ms. Huijuan Zhao served as a member of the management team at Ping’An Bank, where she oversaw services for high net wealth clients and risk control practices from 2019 to 2022. In her prior role as head of marketing and risk control operations at two Jiangsu-based privately owned businesses operating in business and financial service sectors from 2013 to 2019, Ms. Zhao helped build out market expansion and risk control protocols and playbook and played critical supervisory and coaching roles to the growth and expansion of both businesses. She holds a bachelor’s degree in Financial English from Suzhou University, which she received in 2012. Ms. Zhao, our independent director, and Mr. Zhao, our CFO, are not related.
Mr. Yongjun Liu, Chairman of the Company, commented: “We are delighted to welcome Xin, Lianzhang and Huijuan to the Company, all stalwarts in their respective expertise. They are experienced leaders with excellent track records and international background. Their leadership and market insights will help MHUA continue to grow and scale in domestic and international markets, with the goal of achieving strategic transformation of MHUA.”
About Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as eye drop bottles, medicine bottles and anal bags, and Class II and III disposable medical devices, such as identification tape, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, masks, disposable infusion pumps, electronic pumps and puncture kits, which products are sold under its own brands and also sourced and distributed from other manufacturers. The Company has received international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for more than 20 products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for over 30 years, providing more than 800 types of products for domestic sales, as well as 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit www.meihuamed.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development and plans of future business development; financial condition and results of operations; product and service demand and acceptance; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Janice Wang
WFS Investor Relations
Phone:
+86 13811768599
+1 628 283 9214
Email: services@wealthfsllc.com
View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-co-ltd-appoints-new-ceo-cfo-and-directors-301694660.html
SOURCE Meihua International Medical Technologies Co., Ltd.
Related Quotes
Nio (NYSE: NIO) stock spiked Monday morning, but it didn't take long for it to reverse course. The volatility shows just how dynamic the economic situation is in China. Shares of the Chinese EV maker jumped nearly 7% after the market opened, but by 12:40 p.m. ET, Nio stock was down by 1.6%.
DEEP DIVE Stocks of companies that raise dividends consistently have outperformed during this year’s bear market. Below is a screen showing which stocks are analysts’ favorites for next year among an expanded list of Dividend Aristocrats.
Have an issue with your financial adviser or looking for a new one? Email questions and concerns to picks@marketwatch.com.
Yahoo Finance Live looks at cannabis-tied shares following President Biden's signing of a marijuana research bill.
A roundup of recent banking and finance news across Greater Philadelphia: A coalition of 13 Republican state attorneys general wants to stop Vanguard Group from buying shares in U.S. utilities companies due to the investment manager’s environmental, social and governance policies. The attorneys general filed a motion last week to the Federal Energy Regulatory Commission requesting it block Vanguard’s purchase.
Shares of enterprise software giants Snowflake (NYSE: SNOW), Datadog (NASDAQ: DDOG), and MongoDB (NASDAQ: MDB) were plunging on Monday, down by 8.7%, 6.4%, and 9.4%, respectively, as of 3:06 p.m. ET. There wasn't much company-specific news today, although Snowflake reported earnings last week, and MongoDB will report tomorrow. Friday's strong jobs and wages report, combined with today's stronger-than-expected services Purchasing Managers' Index (PMI) reading, showed the economy may be stronger than generally thought — surprising, especially since recent financial results and guidance in the software industry have been less than stellar.
On top of strong dividend growth, all three stocks have displayed remarkable relative strength in 2022, outperforming the general market handily.
Oil prices are currently down by more than 30% from their 52-week highs, but analysts still see opportunity in energy stocks
Elon Musk's group and its Chinese rivals are often among the choices of investors betting on electric vehicles.
In this article, we will take a look at the 11 best quality stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best Quality Stocks to Buy Now. During these uncertain times, when the Federal Reserve is on a mission to fight inflation by increasing benchmark […]
In this article, we will discuss the 12 best undervalued energy stocks to buy. If you want to explore similar stocks, you can also take a look at 5 Best Undervalued Energy Stocks to Buy. 2022 has been the year for energy stocks. While all sectors of the economy fluctuated, the energy sector remained relatively […]
Many people wonder whether they should be investing in qualified or non-qualified dividends and what the differences are. The largest difference is in how each is taxed. To help you determine what stock paying dividends could have a place in … Continue reading → The post Qualified vs. Non-Qualified Dividends appeared first on SmartAsset Blog.
Shares of small- and mid-cap Chinese stocks including Tuya (NYSE: TUYA), EHang (NASDAQ: EH), and Lufax (NYSE: LU) were moving higher today after China again took another step away from its zero-COVID policy, boosting investor confidence that the economy would fully reopen in the coming months. Over the weekend, Beijing and Shenzhen announced that they would lift requirements that commuters show negative COVID tests before travel.
Despite the soft economic backdrop, 2022 has still provided several large-scale takeovers. Microsoft’s acquisition of Activision Blizzard ($68.7 billion – expected to close next year), Broadcom’s of VMWare (~$61 billion – by the end of next year, too) and Oracle’s of Cerner ($28.3 billion), are all notable deals that readily come to mind. For companies, a lot of the time, larger is preferable; smaller businesses can take advantage of cost-savings that larger organizations have, while bigger enti
(Bloomberg) — There’s a hidden risk to the global financial system embedded in the $65 trillion of dollar debt being held by non-US institutions via currency derivatives, according to the Bank for International Settlements. Most Read from Bloomberg‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernStocks Hit by Fed-Hike Jitters as US Yields Surge: Markets WrapElon Musk’s Impossible Electric Truck Is Getting the Last LaughAmbitious Plans to Build Indonesia a Brand New Capital
Shares of telecom giant Lumen Technologies (NYSE: LUMN) plunged 25.7% in November, according to data from S&P Global Market Intelligence. It wasn't difficult to ascertain why Lumen fell last month: The company announced on its Nov. 2 earnings call that it suspended its generous dividend. In the third quarter, Lumen once again disappointed the markets, with revenue declining 10.2% and non-generally accepted accounting principles (adjusted) earnings per share of $0.14 missing estimates by a wide $0.21.
With a yield of 9.62%, the recently expired Series I bond was understandably popular. With interest rates rising, bond funds are down this year and banks continue to offer miserly rates on deposit accounts. So it's no wonder that a … Continue reading → The post It Pays to Procrastinate: The New 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years appeared first on SmartAsset Blog.
The founder of the bankrupt cryptocurrency exchange launched a media blitzkrieg to give his version of his downfall.
As investors begin to see light at the end of the Federal Reserve rate-hike tunnel, real estate investment trusts (REITs) are bouncing back off their lows of six weeks ago. Now could be an ideal time to start building a basket of REIT stocks. But with 208 REITs to choose from, how does an investor know which ones make the best purchases? Take a look at five well-established REITs from diversified subsectors that have high-quality, long-term total returns (appreciation plus nonreinvested dividend
After a punishing 2022, it may be time to bet on bonds backed by the U.S. government, particularly if a recession hits, according to Truist Advisory Services.